JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR ...

INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown antiinflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that INF904 has minimal inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Reported results from a first-in-human study demonstrated ...

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 cli ...

Core Insights - InflaRx N.V. is advancing its oral small molecule C5aR inhibitor, INF904, targeting chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) as part of its immuno-dermatology development strategy [1][4][10] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary technologies to develop inhibitors of the complement activation factor C5a and its receptor C5aR [12] - The company was founded in 2007 and has operations in Germany and the USA [12] Product Development - INF904 is designed to inhibit C5a-induced signaling and has shown promise in pre-clinical models for its anti-inflammatory effects [11] - The company plans to initiate a Phase 2a basket trial for INF904 by the end of 2024, involving 75 patients with moderate-to-severe CSU and HS [5][6] - The trial will assess safety, pharmacokinetics (PK), and preliminary efficacy over a 4-week treatment period, with data expected in summer 2025 [6][8] Clinical Trial Design - The CSU group will include 45 patients randomized to receive INF904 at doses of 30 mg and 90 mg twice daily [7] - Efficacy measures for CSU will include changes in Urticaria Activity Score 7 (UAS7) and other patient-reported outcomes [7] - The HS group will consist of 30 patients receiving doses of 30 mg, 60 mg, or 90 mg twice daily, with similar efficacy measures [9] Market Potential - The commercial assessment indicates that CSU and HS represent multi-billion-dollar market opportunities, highlighting a significant unmet medical need for effective treatments [8][10] - INF904 is viewed as a "pipeline-in-a-product," with potential applications extending beyond immuno-dermatology to areas such as nephrology, neurology, and hematology [10] Financial Position - InflaRx's strong financial position is expected to support operations and clinical program advancements into 2026 [8]

JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor, INF904. Speakers provided additional details on development rationales and plans for INF904, as well as additional insight into its potential role in CSU and HS and its broader therapeutic potential in the immuno-inflammation field. P ...

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET. The poster is titled, "Vilobelima ...

Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human inflammatory diseases INF904 multiple ascending dose (MAD) pharmacokinetic (PK) and pharmacodynamic (PD) data supporting best-in-class potential announced, and plans to initiate Phase IIa in CSU and HS by the end of 2024, with data availability anticipated i ...

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City. InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT / 8:30 PM CEST. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) ...

Exhibit 99.1 InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans InflaRx will host a virtual pipeline update call today, beginning at 8:00 AM ET / 1:00 PM CET to discuss its focus on immuno- dermatology. The company will provide details on the development rationales for its chosen indications for its oral C5aR inhibitor INF904 and provide an update on the development of vilobelimab in PG. To participate in the conference call, participants may pre-register at https://us06web.zoom.u ...